{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T01:04:54Z","timestamp":1696467894637},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s10637-013-0010-4","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T03:15:06Z","timestamp":1377054906000},"page":"1487-1498","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies\u2014results of a phase I dose-escalation study"],"prefix":"10.1007","volume":"31","author":[{"given":"Normand","family":"Blais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Souli\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami G.","family":"Diab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ruiz-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Thall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Q.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4161\/cbt.2.5.446","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471\u2013478","journal-title":"Mol Cancer Ther"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884\u2013896","journal-title":"J Clin Oncol"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1210\/jc.2005-2845","volume":"91","author":"DW Kim","year":"2006","unstructured":"Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070\u20134076","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR4","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","volume":"20","author":"LJ Murray","year":"2003","unstructured":"Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O\u2019Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757\u2013766","journal-title":"Clin Exp Metastasis"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","volume":"101","author":"AM O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597\u20133605","journal-title":"Blood"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/ijc.22999","volume":"121","author":"Y Hasumi","year":"2007","unstructured":"Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121:2606\u20132614","journal-title":"Int J Cancer"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/bjc.1997.83","volume":"75","author":"MI Koukourakis","year":"2007","unstructured":"Koukourakis MI, Giatromanolaki A, O\u2019Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (2007) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477\u2013481","journal-title":"Br J Cancer"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"7241","DOI":"10.1158\/0008-5472.CAN-04-4171","volume":"65","author":"Y Shikada","year":"2005","unstructured":"Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, Sata S, Nakagawa K, Yoshino I, Maehara Y, Sueishi K (2005) Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 65:7241\u20137248","journal-title":"Cancer Res"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.2001.19.2.432","volume":"19","author":"A Yuan","year":"2001","unstructured":"Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432\u2013441","journal-title":"J Clin Oncol"},{"key":"10_CR11","volume-title":"SUTENT, summary of product characteristics","author":"PI Sutent","year":"2012","unstructured":"Sutent PI (2012) SUTENT, summary of product characteristics. Pfizer Inc., New York"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","volume":"26","author":"MA Socinski","year":"2008","unstructured":"Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650\u2013656","journal-title":"J Clin Oncol"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","volume":"101","author":"S Novello","year":"2009","unstructured":"Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 101:1543\u20131548","journal-title":"Br J Cancer"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"M Kulke","year":"2008","unstructured":"Kulke M, Lenz HJ, Meropol N, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403\u20133410","journal-title":"J Clin Oncol"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul J-L, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, H\u00f6rsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501\u2013513","journal-title":"N Engl J Med"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4068\u20134075","journal-title":"J Clin Oncol"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959\u20131968","journal-title":"Eur J Cancer"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516\u20132524","journal-title":"JAMA"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.juro.2007.07.030","volume":"178","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178:1883\u20131887","journal-title":"J Urol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","volume":"6","author":"AR Hanauske","year":"2001","unstructured":"Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363\u2013373","journal-title":"Oncologist"},{"key":"10_CR21","doi-asserted-by":"crossref","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589\u20131597","DOI":"10.1200\/JCO.2004.08.163"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/1471-2407-8-216","volume":"8","author":"F Russo","year":"2008","unstructured":"Russo F, Bearz A, Pampaloni G, the Investigators of the Italian Pemetrexed Monotherapy of NSCLC Group (2008) Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 8:216","journal-title":"BMC Cancer"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","volume":"24","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24:1443\u20131448","journal-title":"J Clin Oncol"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1200\/JCO.2006.07.7016","volume":"24","author":"M Socinski","year":"2006","unstructured":"Socinski M, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK (2006) Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24:4840\u20134847","journal-title":"J Clin Oncol"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/cncr.21480","volume":"104","author":"RG Zinner","year":"2005","unstructured":"Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS (2005) Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104:2449\u20132456","journal-title":"Cancer"},{"key":"10_CR26","unstructured":"Christensen JG, Hall C, Hollister BA (2008) Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (abstract)"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1158\/0008-5472.CAN-04-1668","volume":"65","author":"PE Huber","year":"2005","unstructured":"Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Gr\u00f6ne HJ, Debus J, Lipson KE, Abdollahi A (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65:3643\u20133655","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.5-suppl_1-20","volume":"5","author":"L Rosen","year":"2000","unstructured":"Rosen L (2000) Antiangiogenic strategies and agents in clinical trials. Oncologist 5(Suppl 1):20\u201327","journal-title":"Oncologist"},{"key":"10_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-71518-6","volume-title":"Angiogenesis: an integrative approach from science to medicine","author":"WD Figg","year":"2008","unstructured":"Figg WD, Folkman J (2008) Angiogenesis: an integrative approach from science to medicine. Springer, New York"},{"key":"10_CR30","doi-asserted-by":"crossref","unstructured":"Heist RS, Wang XF, Hodgson L, Otterson GA, Stinchcombe T, Vokes EE, Socinski AA (2012) CALGB 30704: a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30(suppl; abstr 7513)","DOI":"10.1200\/jco.2012.30.15_suppl.7513"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227\u20131234","journal-title":"J Clin Oncol"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00280-011-1755-0","volume":"69","author":"LQ Chow","year":"2012","unstructured":"Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR (2012) A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol 69:709\u2013722","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.lungcan.2011.05.004","volume":"74","author":"R Gervais","year":"2011","unstructured":"Gervais R, Hainsworth JD, Blais N, Besse B, Laskin J, Hamm JT, Lipton A, Albain KS, Masters GA, Natale RB, Selaru P, Kim ST, Chao RC, Page RD (2011) Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 74:474\u2013480","journal-title":"Lung Cancer"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/JTO.0b013e3181c7307e","volume":"5","author":"MA Socinski","year":"2010","unstructured":"Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF (2010) Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel\/carboplatin in non-small cell lung cancer. J Thorac Oncol 5:354\u2013360","journal-title":"J Thorac Oncol"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2009.12.015","volume":"70","author":"HS Kim","year":"2010","unstructured":"Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY, Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY (2010) A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer 70:71\u201376","journal-title":"Lung Cancer"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810\u20131816","journal-title":"J Clin Oncol"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.lungcan.2010.01.016","volume":"70","author":"M Reck","year":"2010","unstructured":"Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr H-G, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 70:180\u2013187","journal-title":"Lung Cancer"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","volume":"27","author":"EF Smit","year":"2009","unstructured":"Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038\u20132045","journal-title":"J Clin Oncol"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1756-9966-29-38","volume":"29","author":"GZ Zhang","year":"2010","unstructured":"Zhang GZ, Jiao SC, Meng ZT (2010) Pemetrexed plus cisplatin\/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 29:38","journal-title":"J Exp Clin Cancer Res"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdp565","volume":"21","author":"M Kozloff","year":"2010","unstructured":"Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, Miller K (2010) An exploratory study of sunitinib plus paclitaxel as firstline treatment for patients with advanced breast cancer. Ann Oncol 21:1436\u20131441","journal-title":"Ann Oncol"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","volume":"11","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:82\u201392","journal-title":"Clin Breast Cancer"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10637-010-9565-5","volume":"30","author":"I Okamoto","year":"2012","unstructured":"Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Ohki E, Kimura N, Hashimoto J, Nakagawa K (2012) Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Invest New Drugs 30:639\u2013646","journal-title":"Invest New Drugs"},{"key":"10_CR46","first-page":"96","volume":"49","author":"K Mross","year":"2011","unstructured":"Mross K, B\u00fcchert M, Fasol U, Jaehde U, Kanefendt F, Strumberg D, Arends J, Hense J, Moritz B, Fischer R, Scheulen ME (2011) A preliminary report of a phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment. Int J Clin Pharmacol Ther 49:96\u201398","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10_CR47","first-page":"973","volume":"32","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Yamazaki K, Hamaguchi T, Shimada Y, Kato K, Yasui H, Boku N, Lechuga MJ, Hirohashi T, Shibata A, Hashigaki S, Li Y, Ohtsu A (2012) Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-na\u00efve colorectal cancer. Anticancer Res 32:973\u2013979","journal-title":"Anticancer Res"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1200\/JCO.2009.27.7988","volume":"28","author":"W Sun","year":"2010","unstructured":"Sun W, Powell M, O\u2019Dwyer PJ, Catalano P, Ansari RH, Benson AB III (2010) Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28:2947\u20132951","journal-title":"J Clin Oncol"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00280-011-1685-x","volume":"69","author":"B Schultheis","year":"2012","unstructured":"Schultheis B, Kummer G, Zeth M, Brendel E, Xia C, Kornacker M, Strumberg D (2012) Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemother Pharmacol 69:333\u2013339","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","volume":"28","author":"G Scagliotti","year":"2010","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abr\u00e3o Miziara JE, Balint B, De Marinis F, Keller A, Ar\u00e9n O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835\u20131842","journal-title":"J Clin Oncol"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdp489","volume":"21","author":"S Sharma","year":"2010","unstructured":"Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL (2010) A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 21:297\u2013304","journal-title":"Ann Oncol"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","volume":"29","author":"HS Rugo","year":"2011","unstructured":"Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D (2011) Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 29:2459\u20132465","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0010-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10637-013-0010-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0010-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0010-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:41:06Z","timestamp":1678509666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-0010-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-0010-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]},"assertion":[{"value":"1 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}